{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T15:52:13Z","timestamp":1743004333403,"version":"3.40.3"},"publisher-location":"New York, NY","reference-count":29,"publisher":"Springer US","isbn-type":[{"type":"print","value":"9781071631744"},{"type":"electronic","value":"9781071631751"}],"license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023]]},"DOI":"10.1007\/978-1-0716-3175-1_39","type":"book-chapter","created":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T07:02:13Z","timestamp":1684479733000},"page":"597-610","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Chromogenic Factor VIII Assay for Patients with Hemophilia A and on Emicizumab Therapy"],"prefix":"10.1007","author":[{"given":"Olivia A.","family":"Yacoub","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth M.","family":"Duncan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,5,20]]},"reference":[{"key":"39_CR1","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1111\/jth.14315","volume":"16","author":"M Makris","year":"2018","unstructured":"Makris M, Oldenburg J, Mauser-Bunschoten EP, Peerlinck K, Castaman G, Fijnvandraat K (2018) For the subcommittee on Factor VIII, Factor IX and rare bleeding disorders. The definition, diagnosis and management of mild hemophilia A: communication from the SSC of the ISTH. J Thromb Haemost 16:2530\u20132533. https:\/\/doi.org\/10.1111\/jth.14315","journal-title":"J Thromb Haemost"},{"issue":"2","key":"39_CR2","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1055\/s-0038-1642754","volume":"59","author":"A Parquet-Gernez","year":"1988","unstructured":"Parquet-Gernez A, Mazurier C, Goudemand M (1988) Functional and immunological assays of FVIII in 133 haemophiliacs- characterization of a subgroup of patients with mild haemophilia A and discrepancy in 1- and 2-stage assays. Thromb Haemost 59(2):202\u2013206","journal-title":"Thromb Haemost"},{"issue":"4","key":"39_CR3","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1111\/j.1365-2141.1994.tb06749.x","volume":"87","author":"EM Duncan","year":"1994","unstructured":"Duncan EM, Duncan BM, Tunbridge LJ, Lloyd JV (1994) Familial discrepancy between the one-stage and two-stage factor VIII methods in a subgroup of patients with haemophilia A. Br J Haematol 87(4):846\u2013848. https:\/\/doi.org\/10.1111\/j.1365-2141.1994.tb06749.x","journal-title":"Br J Haematol"},{"issue":"2","key":"39_CR4","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1046\/j.1365-2141.1996.d01-1792.x","volume":"94","author":"Z Rudzki","year":"1996","unstructured":"Rudzki Z, Duncan EM, Casey GJ, Neumann M, Favaloro EJ, Lloyd JV (1996) Mutations in a subgroup of patients with mild haemophilia A and a familial discrepancy between the one-stage and two-stage factor VIII:C methods. Br J Haematol 94(2):400\u2013406. https:\/\/doi.org\/10.1046\/j.1365-2141.1996.d01-1792.x","journal-title":"Br J Haematol"},{"issue":"3","key":"39_CR5","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1055\/s-0033-1334863","volume":"39","author":"EM Duncan","year":"2013","unstructured":"Duncan EM, Rodgers SE, McRae SJ (2013) Diagnostic testing for mild Haemophilia A in patients with discrepant one-stage, two-stage and chromogenic FVIII:C assays. Semin Thromb Hemost 39(3):272\u2013282. https:\/\/doi.org\/10.1055\/s-0033-1334863","journal-title":"Semin Thromb Hemost"},{"issue":"12","key":"39_CR6","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.3324\/haematol.2013.08808","volume":"98","author":"AE Bowyer","year":"2013","unstructured":"Bowyer AE, Van Veen JJ, Goodeve AC, Kitchen S, Makris M (2013) Specific and global coagulation assays in the diagnosis of discrepant mild haemophilia A. Haematologica 98(12):1980\u20131987. https:\/\/doi.org\/10.3324\/haematol.2013.08808","journal-title":"Haematologica"},{"issue":"5","key":"39_CR7","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1111\/j.1365-2141.2011.08688.x","volume":"154","author":"AE Bowyer","year":"2011","unstructured":"Bowyer AE, Goodeve A, Liesner R, Mumford AD, Kitchen S, Makris M (2011) p.Tyr365Cys change in factor VIII: haemophilia A, but not as we know it. Br J Haematol 154(5):618\u2013625. https:\/\/doi.org\/10.1111\/j.1365-2141.2011.08688.x","journal-title":"Br J Haematol"},{"issue":"1","key":"39_CR8","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1111\/j.1365-2516.2007.01557.x","volume":"14","author":"H Lyall","year":"2008","unstructured":"Lyall H, Hill M, Westby J, Grimley C, Dolan G (2008) Tyr346\u2192Cys mutation results in factor VIII:C assay discrepancy and a normal bleeding phenotype \u2013 is this mild haemophilia A? Haemophilia 14(1):78\u201380. https:\/\/doi.org\/10.1111\/j.1365-2516.2007.01557.x","journal-title":"Haemophilia"},{"issue":"2","key":"39_CR9","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1111\/j.1751-553X.2007.01021.x","volume":"31","author":"SE Rodgers","year":"2009","unstructured":"Rodgers SE, Duncan EM, Sobieraj-Teague M, Lloyd JV (2009) Evaluation of three automated chromogenic FVIII kits for the diagnosis of mild discrepant haemophilia A. Int J Lab Hematol 31(2):180\u2013188. https:\/\/doi.org\/10.1111\/j.1751-553X.2007.01021.x","journal-title":"Int J Lab Hematol"},{"key":"39_CR10","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/978-1-4939-7196-1","volume":"1646","author":"SE Rodgers","year":"2017","unstructured":"Rodgers SE, Duncan EM (2017) Chromogenic factor FVIII assays for improved diagnosis of haemophilia A. Methods Mol Biol 1646:265\u2013267. https:\/\/doi.org\/10.1007\/978-1-4939-7196-1","journal-title":"Methods Mol Biol"},{"key":"39_CR11","doi-asserted-by":"publisher","first-page":"e295","DOI":"10.1016\/S2352-3026(19)30054-7","volume":"6","author":"S Pipe","year":"2019","unstructured":"Pipe S, Shima M, Lehle M et al (2019) Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, nonrandomised phase 3 study. Lancet 6:e295. https:\/\/doi.org\/10.1016\/S2352-3026(19)30054-7","journal-title":"Lancet"},{"issue":"23","key":"39_CR12","doi-asserted-by":"publisher","first-page":"2463","DOI":"10.1182\/blood-2017-08-801662","volume":"130","author":"PJ Lenting","year":"2017","unstructured":"Lenting PJ, Denis CV, Christophe OD (2017) Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII? Blood 7 130(23):2463\u20132468. https:\/\/doi.org\/10.1182\/blood-2017-08-801662","journal-title":"Blood 7"},{"issue":"21","key":"39_CR13","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1056\/NEJMoa1511769","volume":"374","author":"M Shima","year":"2016","unstructured":"Shima M, Hanabusa H, Taki M (2016) Factor VIII-mimetic function of humanized bispecific antibody in hemophilia A. N Engl J Med 374(21):2044\u20132053","journal-title":"N Engl J Med"},{"issue":"3","key":"39_CR14","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1111\/hae.13990","volume":"26","author":"A Bowyer","year":"2020","unstructured":"Bowyer A, Kitchen S, Maclean R (2020) Effects of emicizumab on APTT, one-stage and chromogenic assays of factor VIII in artificially spiked plasma and in samples from haemophilia A patients with inhibitors. Haemophilia 26(3):536\u2013542. https:\/\/doi.org\/10.1111\/hae.13990","journal-title":"Haemophilia"},{"key":"39_CR15","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1111\/hae.13903","volume":"26","author":"Jenkins","year":"2020","unstructured":"Jenkins et al (2020) Laboratory coagulation tests and emicizumab treatment: UK haemophilia centre doctors\u2019 organisation guideline. Haemophilia 26:151\u2013155. https:\/\/doi.org\/10.1111\/hae.13903","journal-title":"Haemophilia"},{"issue":"7","key":"39_CR16","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1055\/s-0039-1688687","volume":"119","author":"JI Adamkewicz","year":"2019","unstructured":"Adamkewicz JI, Chen DC, Paz-Priel I (2019) Effects and interferences of emicizumab, a humanised bispecific antibody mimicking activated factor VIII cofactor function, on coagulation assays. Thromb Haemost 119(7):1084\u20131093. https:\/\/doi.org\/10.1055\/s-0039-1688687","journal-title":"Thromb Haemost"},{"issue":"Suppl 6","key":"39_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/hae.14046","volume":"26","author":"A Srivastava","year":"2020","unstructured":"Srivastava A, Santagostino E, Dougall A et al (2020) (2020) WFH guidelines for the Management of Hemophilia, 3rd edition. Haemophilia 26(Suppl 6):1\u2013158. https:\/\/doi.org\/10.1111\/hae.14046","journal-title":"Haemophilia"},{"key":"39_CR18","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/hae.13217","volume":"23","author":"J Adamkewicz","year":"2017","unstructured":"Adamkewicz J, Kim B, Steinbusch D, Calatzis A (2017) Measurement of FVIII inhibitor titer using a Chromogenic Bethesda Assay (CBA) in the presence of Emicizumab (ACE 910), a humanized bispecific antibody mimicking FVIIIa cofactor function. Haemophilia 23:3. (Abstract). https:\/\/doi.org\/10.1111\/hae.13217","journal-title":"Haemophilia"},{"issue":"2","key":"39_CR19","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/ijlh.13384","volume":"43","author":"CH Miller","year":"2021","unstructured":"Miller CH, Boylan B, Payne AB, Driggers J, Bean CJ (2021) Validation of the chromogenic Bethesda assay for factor VIII inhibitors in hemophilia a patients receiving Emicizumab. Int J Lab Hematol 43(2):84\u201386. https:\/\/doi.org\/10.1111\/ijlh.13384","journal-title":"Int J Lab Hematol"},{"issue":"1","key":"39_CR20","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1111\/j.1365-2141.2006.06402.x","volume":"136","author":"SE Rodgers","year":"2007","unstructured":"Rodgers SE, Duncan EM, Barbulescu DM, Quinn DM, Lloyd JV (2007) In vitro kinetics of factor VIII activity in patients with mild haemophilia A and a discrepancy between one-stage and two-stage factor VIII assay results. Br J Haematol 136(1):138\u2013145. https:\/\/doi.org\/10.1111\/j.1365-2141.2006.06402.x","journal-title":"Br J Haematol"},{"key":"39_CR21","unstructured":"Biophen FVIII:C. Official product information (2015) Hyphen biomed. Neuille-Sur-Oise, France. D750 02 B1 1406"},{"key":"39_CR22","unstructured":"Factor VIII Chromogenic Assay Instruction for Use (2017) Siemens healthcare diagnostics products GmbH, Marburg Germany. B4238G40E11 Rev. 04 \u2013 en"},{"key":"39_CR23","unstructured":"Chromogenix Coamatic FVIII. Official product information. Updated 2019. Instrumentation Laboratory Company \u2013 Bedford, MA https:\/\/diapharma.com\/wp-content\/uploads\/2021\/01\/K822585-Chromogenix-Coamatic-Factor-VIII-insert-302143-Rev-R6-03-2019-.pdf. Accessed 24 Aug 2022"},{"key":"39_CR24","unstructured":"TCoag TriniCHROM Factor VIII:C Official product information (2016) TCoag Ireland Ltd, Wicklow, Ireland. 200645 09\/2016"},{"key":"39_CR25","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1111\/jth.15425","volume":"19","author":"MV Ovanesov","year":"2021","unstructured":"Ovanesov MV, Jackson JW, Golding B et al (2021) Considerations on activity assay discrepancies in factor VIII and factor IX products. J Thromb Haemost 19:2102\u20132111. https:\/\/doi.org\/10.1111\/jth.15425","journal-title":"J Thromb Haemost"},{"key":"39_CR26","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/978-1-62703-339-8_24","volume":"992","author":"EM Duncan","year":"2013","unstructured":"Duncan EM, Collecutt M, Street A (2013) Nijmegen-Bethesda assay to measure FVIII inhibitors methods. Mol Biol 992:321\u2013333. https:\/\/doi.org\/10.1007\/978-1-62703-339-8_24","journal-title":"Mol Biol"},{"issue":"1","key":"39_CR27","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1097\/01.mbc.0000198990.16598.85","volume":"17","author":"M Bohm","year":"2006","unstructured":"Bohm M, Taschner S, Kretzschmar E et al (2006) Cold storage of citrated whole blood induces dramatic time-dependent losses in factor VIII and von Willebrand factor: potential for misdiagnosis of haemophilia and von Willebrand disease. Blood Coagul Fibrinolysis 17(1):39\u201345. https:\/\/doi.org\/10.1097\/01.mbc.0000198990.16598.85","journal-title":"Blood Coagul Fibrinolysis"},{"key":"39_CR28","volume-title":"CLSI Document H21-A5","author":"CLSI Collection, Transport, and Processing of Blood Specimens for Testing Plasma-Based Coagulation assays and molecular Hemostasis Assays; Approved Guideline- Fifth addition","year":"2008","unstructured":"CLSI Collection, Transport, and Processing of Blood Specimens for Testing Plasma-Based Coagulation assays and molecular Hemostasis Assays; Approved Guideline- Fifth addition (2008) CLSI Document H21-A5. Clinical and Laboratory Standards Institute, Wayne, PA"},{"key":"39_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/ijlh.12004","volume":"35","author":"I Mackie","year":"2013","unstructured":"Mackie I, Cooper P, Lawrie A et al (2013) Guidelines on the laboratory aspects of assays used in haemostasis and thrombosis. Int J Lab Hematol 35:1\u201313. https:\/\/doi.org\/10.1111\/ijlh.12004","journal-title":"Int J Lab Hematol"}],"container-title":["Methods in Molecular Biology","Hemostasis and Thrombosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-3175-1_39","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T07:07:23Z","timestamp":1684480043000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-3175-1_39"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"ISBN":["9781071631744","9781071631751"],"references-count":29,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-3175-1_39","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"type":"print","value":"1064-3745"},{"type":"electronic","value":"1940-6029"}],"subject":[],"published":{"date-parts":[[2023]]},"assertion":[{"value":"20 May 2023","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}